As of my last update in October 2023, there is limited publicly available information regarding the chemical substance known as FHD-286 with the CAS number 2671128-05-3. This compound is likely a research chemical or a pharmaceutical candidate, and specific characteristics such as its molecular structure, physical properties, and biological activity may not be widely documented in standard chemical databases. Typically, substances like FHD-286 may be evaluated for their potential applications in medicinal chemistry, including their efficacy, safety, and mechanism of action in biological systems. Researchers often investigate such compounds for their pharmacological properties, including their interactions with biological targets, solubility, stability, and toxicity. For detailed and specific information, including experimental data and safety profiles, consulting scientific literature or proprietary databases would be necessary. Always ensure to handle any chemical substance with appropriate safety measures and in compliance with relevant regulations.

FHD-286 is a highly potent, selective, allosteric and orally available, small-molecule, enzymatic inhibitor of BRG1 (SMARCA4) and BRM (SMARCA2), two highly similar proteins that are the ATPases, or the catalytic engines of the BAF complex, one of the critical regulators within the chromatin regulatory system. In preclinical studies, FHD-286 has shown anti-tumour activity across a broad range of malignancies, including hematologic and solid tumours. FHD-286 is being developed for relapsed and/or refractory AML.

FHD-286

2671128-05-3: As of my last update in October 2023, there is limited publicly available information regarding the chemical substance known as FHD-286 with the CAS number 2671128-05-3. This compound is likely a research chemical or a pharmaceutical candidate, and specific characteristics such as its molecular structure, physical properties, and biological activity may not be widely documented in standard chemical databases. Typically, substances like FHD-286 may be evaluated for their potential applications in medicinal chemistry, including their efficacy, safety, and mechanism of action in biological systems. Researchers often investigate such compounds for their pharmacological properties, including their interactions with biological targets, solubility, stability, and toxicity. For detailed and specific information, including experimental data and safety profiles, consulting scientific literature or proprietary databases would be necessary. Always ensure to handle any chemical substance with appropriate safety measures and in compliance with relevant regulations.

<p>FHD-286 is an inhibitor of BRM/BRG1 ATPase and can be used for studies on the treatment of BAF-related disorders such as acute myeloid leukemia.</p>

CAS 2671128-05-3

FHD-286

FHD-286

Ref: 54-BUP07735

FHD-286

Ref: TM-T9749